EGFR and non-small cell lung carcinoma: A confirmatory phase III study (AURA 3, ClinicalTrials.gov, NCT02151981) is comparing osimertinib with platinum-based chemotherapy in patients who have advanced EGFR mutation-positive NSCLC, whose disease progressed following first-line EGFR-TKI therapy, and whose tumors harbor EGFRT790M.